Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

other uses of

paclitaxel licensed to BSC and Cook (including uses relating to

Cook's ZILVER(R) PTX paclitaxel-eluting peripheral vascular stent);

(iii) potential royalty and other income from certain other uses of

paclitaxel licensed to Broncus Technologies Incorporated ("Broncus")

relating to the Exhale(R) paclitaxel-eluting lung stent; and (iv)

certain other assets and liabilities not related to the ongoing

business of API. The business of Angiotech prior to the transaction

consists primarily of the business assets to be transferred to API,

and the license agreements with BSC, Cook and Broncus. For the year

ended December 31, 2007, Angiotech had $288 million in revenue, $111

million of which was royalty revenue derived mainly from BSC, and

$177 million of which was product and royalty revenue derived from

the assets to be transferred to API.

- Financing Transaction. The Company has entered into a Note Purchase

Agreement, providing for the issuance and sale of between

$200 million and $300 million of convertible notes to Ares Management

and New Leaf Venture Partners. The convertible notes will have an

initial conversion price of $20 per share, and each $1,000 principal

amount of convertible notes will be convertible into 50 shares of

API, implying an initial equity value for API of $625 million

assuming $75 million in cash and cash equivalents at API at closing

and no debt, other than the guarantees of remaining amounts of

Angiotech's two existing debt issues. The convertible notes will be

convertible into 32% to 48% of the common stock of API, depending

upon the final initial transaction size, calculated on an "if

converted" basis and without taking into account any future dilution

resulting from ad
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... KENILWORTH, N.J., Dec. 10 The Board of Directors of Schering-Plough ... of 6.5 cents per common share. Payment will be made ... of business on Feb. 6, 2009. As of Sept. 30, ... , The Board of Directors today also declared ...
... Published in the Journal Blood for the American Society of ... SOMERSET, N.J., Dec. 10 Alfacell Corporation (Nasdaq: ... annual meeting abstracts in Blood (2008 112: Abstract ... and R-Amphinase (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia ...
... December 10 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SIX ... medical research project findings will be presented ... Care) Congress in,Anaheim, California. These studies confirm ... using Oridion Microstream(R) capnography technology,and clearly show ...
Cached Biology Technology:Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... The Quaking gene, first described as a mutation in ... tumor formation and protect humans from cancer. , ... the University of Wisconsin has shown that the Quaking ... a protein associated with GLI1, a cancer-causing oncogene highly ...
... Research Center at Oregon Health & Science University (OHSU) ... how stem cells become various kinds of brain cells. ... Parkinson's disease, brain and spinal cord injury, and other ... lost or damaged brain cells. The research is published ...
... olive oil, which have antioxidant, anti-inflammatory and anti-clotting ... the so-called Mediterranean Diet, according to a new ... the Journal of the American College of Cardiology. ... of the Mediterranean diet on cardiovascular disease and ...
Cached Biology News:Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3OHSU discovery sheds light into how stem cells become brain cells 2Phenolic compounds may explain Mediterranean diet benefits 2Phenolic compounds may explain Mediterranean diet benefits 3
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known maize microRNAs ...
...
Biology Products: